LYRICA (pregabalin) binds with high affinity to the alpha2-delta site (an auxiliary subunit of voltage-gated calcium channels) in central nervous system tissues.

LYRICA is indicated for: Neuropathic pain associated with diabetic peripheral neuropathy (DPN); Postherpetic neuralgia (PHN); Adjunctive therapy for the treatment of partial-onset seizures in patients 1 month of age and older; Fibromyalgia; Neuropathic pain associated with spinal cord injury.

Begin dosing at 50 mg three times a day (150 mg/day). The dose may be increased to 300 mg/day within 1 week based on efficacy and tolerability. For adult indications, begin dosing at 150 mg/day. For partial-onset seizure dosing in pediatric patients 1 month of age and older, refer to label. (See Full Prescribing Information.)

Most common adverse reactions (greater than or equal to 5% and twice placebo) in adults are dizziness, somnolence, dry mouth, edema, blurred vision, weight gain, and thinking abnormal (primarily difficulty with concentration/attention). Most common adverse reactions (greater than or equal to 5% and twice placebo) in pediatric patients for the treatment of partial-onset seizures are increased weight and increased appetite.

LYRICA is contraindicated in patients with known hypersensitivity to pregabalin or any of its components.

There have been postmarketing reports of angioedema, Hypersensitivity reactions, increase the risk of suicidal thoughts or behavior, Respiratory depression, dizziness and somnolence and impair patients' ability to drive or operate machinery. (See Full Prescribing Information.)